Results 121 to 130 of about 11,862,011 (403)
Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]
, 2018 Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal +8 more
core +2 more sources
Brodalumab: Six-Year US Pharmacovigilance Report
Dermatology and TherapyIntroduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost ...
Mark G. Lebwohl +8 more
doaj +1 more source
Dermatology Practical & ConceptualIntroduction: Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and ...
Eugenia Veronica Di Brizzi +15 more
doaj +1 more source
PLoS ONE, 2020 BackgroundPsoriasis is associated with hyperlipidemia. Few studies have examined the association among psoriasis, hyperlipidemia, and chronic kidney disease (CKD).
Kwei-Lan Liu +3 more
doaj +1 more source
Adalimumab for the treatment of psoriasis
Health Technology Assessment, 2009 This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of adalimumab for the treatment of moderate to severe plaque psoriasis based upon a review of the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA ...
Turner, D. +3 more
openaire +4 more sources
Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. [PDF]
, 2019 Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of
Lee, Erica B +4 more
core
Microarray analyses demonstrate the involvement of type i interferons in psoriasiform pathology development in D6-deficient mice [PDF]
, 2013 The inflammatory response is normally limited by mechanisms regulating its resolution. In the absence of resolution, inflammatory pathologies can emerge, resulting in substantial morbidity and mortality.
Baldwin, H.M. +9 more
core +1 more source
Arthritis &Rheumatology, EarlyView.Objective This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high‐resolution peripheral quantitative computed tomography (HR‐pQCT). Methods This was a phase 4, double‐blind, randomized, placebo‐controlled trial.
Yingzhao Jin +11 more
wiley +1 more source
LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment [PDF]
, 2014 Psoriasis is an immune-mediated highly heterogeneous skin disease in which genetic as well as environmental factors play important roles. In spite of the local manifestations of the disease, psoriasis may progress to affect organs deeper than the skin ...
Blackburn, Gavin J. +7 more
core +3 more sources